Rani Therapeutics Holdings Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 3.1, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Rani Therapeutics Holdings Inc in Mar 31 2026 quarter, has decreased to 118 days, compared to 148 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector Rani Therapeutics Holdings Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Rani Therapeutics Holdings Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RANI Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	240.33 %	-	-	-	-
Y / Y Revenue Change	893.02 %	42.12 %	-	-	-
Receivable Turnover Ratio (TTM)	3.1	2.47	8	8	8
RANI's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	118	148	46	46	46
Seq. Receivable Change	0 %	-	-	-	-
Seq. Revenue Change	16.91 %	-	-	-	-83.27 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

RANI Company Profile • Back to RANI Efficiency Comparisons • Compare RANI Receivables Turnover Ratio to its Competitors

Financial Statements
Rani Therapeutics Holdings Inc 's Accounts Receivable	$ 2 Millions	Visit RANI's Balance sheet
Rani Therapeutics Holdings Inc 's Sales TTM	$ 3 Millions	Visit RANI's Income Statement
Sources of RANI's Revenues		Visit RANI's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RANI's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RANI's Growth Rates	RANI's Roa	RANI's Inventory Turnover Ratio	RANI's Dividend Comparisons
RANI's Profitability Ratios	RANI's Roi	RANI's Asset Turnover Ratio	RANI's Dividend Growth
RANI's Valuation Ratios	RANI's Roe	RANI's Financial Strength Ratios	RANI's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Lantheus Holdings Inc	4.26	$ 1,545.174 Millions	$ 362.753 Millions
Sera Prognostics Inc	4.22	$ 0.057 Millions	$ 0.014 Millions
Fulgent Genetics Inc	4.22	$ 319.019 Millions	$ 75.604 Millions
Vanda Pharmaceuticals Inc	4.21	$ 217.782 Millions	$ 51.748 Millions
Revvity Inc	4.18	$ 2,902.407 Millions	$ 694.362 Millions
Vivosim Labs Inc	4.16	$ 0.131 Millions	$ 0.032 Millions
Vericel Corporation	4.15	$ 292.086 Millions	$ 70.433 Millions
Ptc Therapeutics inc	4.13	$ 827.110 Millions	$ 200.187 Millions
Apyx Medical Corp	4.11	$ 55.304 Millions	$ 13.443 Millions
Butterfly Network Inc	4.07	$ 102.639 Millions	$ 25.225 Millions
Inspiremd Inc	4.07	$ 10.044 Millions	$ 2.470 Millions
Pro dex Inc	4.05	$ 74.636 Millions	$ 18.438 Millions
Dexcom Inc	4.05	$ 4,817.200 Millions	$ 1,190.775 Millions
Gyre Therapeutics Inc	4.04	$ 117.049 Millions	$ 28.979 Millions
Ironwood Pharmaceuticals inc	4.03	$ 361.514 Millions	$ 89.782 Millions
Immunitybio inc	4.02	$ 140.977 Millions	$ 35.064 Millions
Upstream Bio Inc	4.00	$ 3.322 Millions	$ 0.831 Millions
Dyadic International Inc	3.97	$ 3.808 Millions	$ 0.959 Millions
Newamsterdam Pharma Company N v	3.93	$ 22.565 Millions	$ 5.739 Millions
Iovance Biotherapeutics inc	3.93	$ 285.608 Millions	$ 72.726 Millions
Teva Pharmaceutical Industries Limited	3.91	$ 14,139.000 Millions	$ 3,619.000 Millions
Precigen Inc	3.86	$ 31.595 Millions	$ 8.185 Millions
Outset Medical Inc	3.84	$ 116.783 Millions	$ 30.376 Millions
Insight Molecular Diagnostics Inc	3.79	$ 1.949 Millions	$ 0.514 Millions
Biomarin Pharmaceutical Inc	3.75	$ 3,242.316 Millions	$ 864.562 Millions
Adma Biologics Inc	3.75	$ 507.766 Millions	$ 135.423 Millions
Akebia Therapeutics Inc	3.74	$ 232.404 Millions	$ 62.150 Millions
Procept Biorobotics Corporation	3.72	$ 321.012 Millions	$ 86.311 Millions
Waters Corporation	3.71	$ 3,770.581 Millions	$ 1,015.109 Millions
Eli Lilly And Company	3.71	$ 72,249.500 Millions	$ 19,498.700 Millions

Date modified: 2026-07-07T13:21:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.